By Nqobile Dludla JOHANNESBURG, March 4 (Reuters) - Aspen Pharmacare aims to secure sub‑Saharan African approval for Eli Lilly's blockbuster weight‑loss drug Mounjaro ‌as early as this year, its CEO said on Wednesday, capitalising ‌on soaring regional demand for obesity treatments. South Africa-based Aspen’s push to register Mounjaro across the ​region signals its bid to become a key manufacturing and distribution partner for global drugmakers eyeing one of the last major untapped markets for GLP‑1 weigh ...

Denmark’s economy is poised to expand at the fastest pace in the Nordic region this year, even as pharmaceutical giant Novo Nordisk grapples with slowing sales, according to the country’s largest lender https://t.co/Ci3h63C9v5 ...

US FDA warns Novo for second time about misleading drug advertising | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023. REUTERS/Lee Smith [Purchase Licensing Rights, opens new tab]- Companies[Novo Nordisk A/S]Follow[U.S. Food and Drug Administration]FollowMarch 3 (Reuters) - The U.S. Food and Drug Administration has told Novo Nordisk [(NO ...

整理 | GLP1减重宝典内容团队 2026年3月3日，诺和诺德宣布其司美格鲁肽注射液的新适应症在中国已提交上市申请，并拟纳入优先审评。这一新适应症旨在治疗伴有中至重 度肝纤维化的代谢相关脂肪性肝炎（MASH）患者，特别是针对F2-F3期的非肝硬化成人患者。 司美格鲁肽的全球影响力 司美格鲁肽作为诺和诺德的旗舰药物，早在2025年8月已获得美国FDA批准，用于治疗伴有中度到重度肝纤维化的非肝硬化MASH患者，且要 求联合低热量饮食和增加体力活动。此次中国的申报，是基于ESSENCE临床试验的部分结果。该试验评估了每周一次注射2.4mg司美格鲁肽的 疗效，结果显示，司美格鲁肽在改善肝纤维化和脂肪性肝炎消退方面，均表现出优于安慰剂的统计学显著性。 临床试验结果 ESSENCE试验的第一阶段结果表明，使用司美格鲁肽的患者在改善肝纤维化和消退脂肪性肝炎方面，达到了以下临床指标： 在第72周时，36.8%的患者实现了"肝纤维化改善且无脂肪性肝炎恶化"，而安慰剂组仅为22.4%。 62.9%的患者达到了"脂肪性肝炎消退且无肝纤维化恶化"的效果，而安慰剂组为34.3%。 作为诺和诺德的明星药物，司美格鲁肽的销售表现十分亮眼 ...

The Novo Nordisk ( NVO ) ( NONOF ) story keeps getting hammered by the markets. Every time it goes down by 10-20%, it seems the valuations have hit rock bottom, only for more downside to emerge. The latest roundI am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management. My focus is on equity valuation, market trends, and portfolio optimization to uncover high-growth investment opportunities. As a former Vice President at Barclays, I led teams in m ...

Novo Nordisk has invested €432m ($501m) to upgrade its facility in Ireland to ensure the drugmaker can meet the anticipated high demand for oral weight loss drugs. Novo’s site in Monksland, Athlone, is one of 16 facilities the company has across the world. The expansion of the 45-acre tabletting facility is expected to be completed by 2028, though construction has already begun. The site’s existing 260 employees will focus on delivering oral glucagon-like peptide-1 receptor agonists (GLP-1RAs). The Dani ...

Company Strategy - Roche aims for a double-digit market share in the weight loss market, seeking to close the gap with its competitor Novo Nordisk [1] - The CEO of Roche, Thomas Schinecker, expressed the expectation to be among the top three players in the market at the very least [1]

// 热点头条 // 1. 英伟达：宣布向光模块龙头Coherent与Lumentum分别注资20亿美元，合作开发先进光学技术；同时 计划发布专为OpenAI等客户定制的全新AI处理器，整合Groq设计的芯片，预计下月在GTC开发者大会 公布。此外，公司还联手诺基亚与思科等巨头推进AI-RAN与6G生态，签署多项商用合作，发布电信场 景LTM与自主网络蓝图。 2. 苹果：推出了其入门级智能手机的最新版本iPhone 17e，以及一款速度更快的iPad Air，起售价依然为 599美元，拉开了新一轮产品发布的序幕；已暂时关闭其位于阿联酋的全部5家Apple Store零售店，涵盖 阿布扎比3家门店和迪拜2家门店，关闭状态将至少持续至当地时间3月4日，公司未说明具体关闭原因， 但强调将密切关注当地情况并及时更新门店运营信息。 3. 阿里巴巴：阿里巴巴集团内部已完成对AI核心品牌的统一。调整后，阿里巴巴AI的总称和核心品牌 确定为"千问"。其中，千问大模型（Qwen）涵盖基础大模型和专业领域模型，千问APP是阿里巴巴在C 端的旗舰AI应用。3月2日，千问首款AI硬件——"千问AI眼镜"发布，开启线上线下全渠道"0元 ...

Novo Nordisk (NYSE: NVO) stock has been a trainwreck of late. In just the past 12 months, the Danish healthcare stock has lost around 60% of its value. Things have been going from bad to worse for the business. Its guidance hasn't been looking good, and investors are now also concerned about its long-term prospects and ability to compete alongside rival Eli Lilly. While Novo Nordisk does have an approved GLP-1 weight loss pill on the market, the concern is that its advantage won't last long once Eli Lilly ...

In this articleNVOLLYNVONovo Nordisk is investing 432 million euros ($506 million) in a facility in Ireland as it expands its production capacities to make the newly launched Wegovy pill, the Danish drugmaker said Monday. The news comes about two months after Novo launched its blockbuster weight loss drug Wegovy in pill form in the U.S. market, in what has been described as one of the strongest launches ever. "With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities f ...